Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 3/20 | 0.44 |
| ▸ | IGF1R | P08069 | 3/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16145859 | 0.90 | ALPG (0.50) | ARG1ALPLALPGPLAAINSR | |
| SCHEMBL16145983 | 0.87 | ARG1 (0.46) | ARG1ALPLALPGPLAAINSR | |
| SCHEMBL16146669 | 0.83 | KDM4E (0.41) | QPCTKMT2A | |
| SCHEMBL4923723 | 0.83 | PRKAA1 (0.45) | ARG1ALPLALPGPLAAINSR | |
| SCHEMBL16146629 | 0.83 | PRMT1 (0.50) | POLBKMT2A | |
| SCHEMBL16146439 | 0.83 | STAT3 (0.43) | — | |
| SCHEMBL16147165 | 0.82 | CDK1 (0.48) | CDK1POLBKMT2A | |
| SCHEMBL16146503 | 0.81 | STAT3 (0.48) | HTR2BTMIGD3HTR2C | |
| SCHEMBL16146230 | 0.81 | TMIGD3 (0.56) | SRCCDK1HTR2BKMT2ATMIGD3 | |
| SCHEMBL16146149 | 0.81 | PPARG (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | ARG1 637/4885ALPL 2322/4885ALPG 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.